D.K. Pharma Tech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-12-2024
- Paid Up Capital ₹ 1.00 M
as on 16-12-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 32.87%
(FY 2022)
- Profit 930.56%
(FY 2022)
- Ebitda 184.28%
(FY 2022)
- Net Worth 39.94%
(FY 2022)
- Total Assets 13.82%
(FY 2022)
About D.K. Pharma Tech
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Karan Bakshi, Ravindra Sharma, and Rakesh Bakshi serve as directors at the Company.
- CIN/LLPIN
U24100MH2017PTC292880
- Company No.
292880
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Mar 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at D.K. Pharma Tech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karan Bakshi  | Director | 05-Aug-2024 | Current |
| Ravindra Sharma | Director | 05-Aug-2024 | Current |
| Rakesh Bakshi | Director | 25-Mar-2019 | Current |
Financial Performance of D.K. Pharma Tech.
Kajay Pharmachem Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 32.87% increase. The company also saw a substantial improvement in profitability, with a 930.56% increase in profit. The company's net worth Soared by an impressive increase of 39.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of D.K. Pharma Tech?
In 2023, D.K. Pharma Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
D.K. Livkon Healthcare Private LimitedActive 10 years 9 monthsKaran Bakshi and Rakesh Bakshi are mutual person
D K Pharma Chem Private LimitedActive 35 years 3 monthsKaran Bakshi and Rakesh Bakshi are mutual person
Eco Green Industries Private LimitedActive 24 years 10 monthsKaran Bakshi and Rakesh Bakshi are mutual person
- D.K. Biopharma Private LimitedActive 6 years 6 months
Karan Bakshi and Rakesh Bakshi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at D.K. Pharma Tech?
Unlock and access historical data on people associated with D.K. Pharma Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of D.K. Pharma Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D.K. Pharma Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
